NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

But what if they hit the new primary endpoints but miss on the original trial endpoints?

Many trials are good news despite failing some secondaries.

Do they have to disclose such mixed results? What if they do not know how the FDA will perceive them until the post P3 meeting? Are they good or bad?

This trial is way past the bounds of applying a simple pass/fail metric to it.